-
International Journal of Molecular... Dec 2021Human cancer has been depicted as a non-linear dynamic system that is discontinuous in space and time, but progresses through different sequential states (Figure 1)...
Human cancer has been depicted as a non-linear dynamic system that is discontinuous in space and time, but progresses through different sequential states (Figure 1) [...].
Topics: Disease Progression; Humans; Immune System; Neoplasms
PubMed: 34948072
DOI: 10.3390/ijms222413275 -
Journal of Clinical Periodontology Apr 2020To investigate the role of Epstein-Barr virus (EBV), cytomegalovirus (CMV), and anaerobic bacteria in the progression of periodontitis. (Randomized Controlled Trial)
Randomized Controlled Trial
AIM
To investigate the role of Epstein-Barr virus (EBV), cytomegalovirus (CMV), and anaerobic bacteria in the progression of periodontitis.
METHODS
Eighty-one adults with generalized moderate to severe periodontitis were randomly assigned to: oral hygiene or scaling and root planning ± placebo or polyunsaturated fatty acids fish oil. Subgingival plaque samples collected from three healthy and three disease sites at weeks 0, 16, and 28 and from sites demonstrating disease progression were analysed for EBV, CMV, P. gingivalis (Pg), T. forsythia (Tf), and T. denticola (Td) DNA using quantitative polymerase chain reaction.
RESULTS
Cytomegalovirus was detected in 0.3% (4/1454) sites. EBV was present in 12.2% of healthy sites (89/728) and 27.6% disease sites (201/726; p < .0001), but was in low copy number. Disease progression occurred in 28.4% of participants (23/81) and developed predominantly at sites identified as diseased (75/78; 96.2%). CMV and EBV were not associated with disease progression (p = .13) regardless of treatment. In contrast, disease sites were associated with higher levels of Pg, Td, Tf, and total bacteria, and sites that exhibited disease progression were associated with an abundance of Td and Tf (p < .04).
CONCLUSION
Disease progression was associated with Gram-negative anaerobic bacteria; not EBV or CMV.
Topics: Adult; Cytomegalovirus; Disease Progression; Herpesviridae; Herpesvirus 4, Human; Humans; Periodontitis
PubMed: 31860742
DOI: 10.1111/jcpe.13239 -
Praxis 2021
Topics: COVID-19; Disease Progression; Humans; SARS-CoV-2
PubMed: 33834881
DOI: 10.1024/1661-8157/a003679 -
International Journal of Medical... Jul 2023Early recognition and prevention are crucial for reducing the risk of disease progression. This study aimed to develop a novel technique based on a temporal disease... (Review)
Review
OBJECTIVE
Early recognition and prevention are crucial for reducing the risk of disease progression. This study aimed to develop a novel technique based on a temporal disease occurrence network to analyze and predict disease progression.
METHODS
This study used a total of 3.9 million patient records. Patient health records were transformed into temporal disease occurrence networks, and a supervised depth first search was used to find frequent disease sequences to predict the onset of disease progression. The diseases represented nodes in the network and paths between nodes represented edges that co-occurred in a patient cohort with temporal order. The node and edge level attributes contained meta-information about patients' gender, age group, and identity as labels where the disease occurred. The node and edge level attributes guided the depth first search to identify frequent disease occurrences in specific genders and age groups. The patient history was used to match the most frequent disease occurrences and then the obtained sequences were merged together to generate a ranked list of diseases with their conditional probability and relative risk.
RESULTS
The study found that the proposed method had improved performance compared to other methods. Specifically, when predicting a single disease, the method achieved an area under the receiver operating characteristic curve (AUC) of 0.65 and an F1-score of 0.11. When predicting a set of diseases relative to ground truth, the method achieved an AUC of 0.68 and an F1-score of 0.13.
CONCLUSION
The ranked list generated by the proposed method, which includes the probability of occurrence and relative risk score, can provide physicians with valuable information about the sequential development of diseases in patients. This information can help physicians to take preventive measures in a timely manner, based on the best available information.
Topics: Humans; Male; Female; Disease Progression; Risk Factors
PubMed: 37104895
DOI: 10.1016/j.ijmedinf.2023.105068 -
Cells Jun 2022Epigenetic changes drive early embryonic and later stages of development [...].
Epigenetic changes drive early embryonic and later stages of development [...].
Topics: Cell Differentiation; Disease Progression; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Humans
PubMed: 35741035
DOI: 10.3390/cells11121907 -
Nature Reviews. Clinical Oncology Sep 2023
Topics: Humans; Disease Progression; Pyrimidines; Pyrroles
PubMed: 37311901
DOI: 10.1038/s41571-023-00790-x -
Endocrinology and Metabolism Clinics of... Mar 2024Those with concerning signs or symptoms should be evaluated for type 1 diabetes (T1D). Those with first-degree relatives with T1D or based on the presence of high-risk... (Review)
Review
Those with concerning signs or symptoms should be evaluated for type 1 diabetes (T1D). Those with first-degree relatives with T1D or based on the presence of high-risk genes are at increased risk and benefit from screening. Universal screening should be considered in light of new potential therapies to delay disease progression. Although oral glucose tolerance test is the gold standard for T1D staging, there are multiple tools available when oral glucose tolerance test is not feasible. Risk score calculations increase the ability to predict disease progression. Testing should be repeated when symptoms of overt diabetes mellitus are not present.
Topics: Humans; Diabetes Mellitus, Type 1; Risk Factors; Disease Progression
PubMed: 38272595
DOI: 10.1016/j.ecl.2023.09.008 -
Trends in Molecular Medicine Sep 2022The environmental role in disease progression has been appreciated for decades; however, understanding how airborne toxicant exposure can affect organs beyond the lungs... (Review)
Review
The environmental role in disease progression has been appreciated for decades; however, understanding how airborne toxicant exposure can affect organs beyond the lungs is an underappreciated area of scientific inquiry. Particulate matter (PM) includes various gases, liquids, and particles in suspension and is produced by industrial activities such as fossil fuel combustion and natural events including wildfires and volcanic eruptions. Although agencies have attempted to reduce acceptable airborne particulate levels, with urbanization and population growth, these policies have been only moderately effective in mitigating disease progression. A growing area of research is focused on the role of PM exposure in the progression of Alzheimer's disease (AD). This review will summarize the knowns and unknowns of this expanding field.
Topics: Air Pollutants; Air Pollution; Alzheimer Disease; Disease Progression; Humans; Particulate Matter
PubMed: 35840480
DOI: 10.1016/j.molmed.2022.06.004 -
Chinese Medical Journal Jun 2023Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by progressive lung fibrogenesis and histological features of usual interstitial... (Review)
Review
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease characterized by progressive lung fibrogenesis and histological features of usual interstitial pneumonia. IPF has a poor prognosis and presents a spectrum of disease courses ranging from slow evolving disease to rapid deterioration; thus, a differential diagnosis remains challenging. Several biomarkers have been identified to achieve a differential diagnosis; however, comprehensive reviews are lacking. This review summarizes over 100 biomarkers which can be divided into six categories according to their functions: differentially expressed biomarkers in the IPF compared to healthy controls; biomarkers distinguishing IPF from other types of interstitial lung disease; biomarkers differentiating acute exacerbation of IPF from stable disease; biomarkers predicting disease progression; biomarkers related to disease severity; and biomarkers related to treatment. Specimen used for the diagnosis of IPF included serum, bronchoalveolar lavage fluid, lung tissue, and sputum. IPF-specific biomarkers are of great clinical value for the differential diagnosis of IPF. Currently, the physiological measurements used to evaluate the occurrence of acute exacerbation, disease progression, and disease severity have limitations. Combining physiological measurements with biomarkers may increase the accuracy and sensitivity of diagnosis and disease evaluation of IPF. Most biomarkers described in this review are not routinely used in clinical practice. Future large-scale multicenter studies are required to design and validate suitable biomarker panels that have diagnostic utility for IPF.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Biomarkers; Lung Diseases, Interstitial; Lung; Bronchoalveolar Lavage Fluid; Disease Progression; Prognosis
PubMed: 37130223
DOI: 10.1097/CM9.0000000000002171 -
Current Heart Failure Reports Jun 2022To quantify the prevalence of asymptomatic pre-heart failure (pre-HF), progression to more severe stages, and associated mortality. (Review)
Review
PURPOSE OF REVIEW
To quantify the prevalence of asymptomatic pre-heart failure (pre-HF), progression to more severe stages, and associated mortality.
RECENT FINDINGS
A systematic review was conducted between 01 January 2010 and 12 March 2020 (PROSPERO: CRD42020176141). Data of interest included prevalence, disease progression, and mortality rates. In total, 1030 sources were identified, of which, 12 reported on pre-HF (using the ACC/AHA definition for stage B HF) and were eligible. Prevalence estimates of pre-HF ranged from 11 to 42.7% (10 sources) with higher estimates found in the elderly, in patients with hypertension, and in men. Three studies reported on disease progression with follow-up ranging from 13 months to 7 years. The incidence of symptomatic HF (HF/advanced HF) ranged from 0.63 to 9.8%, and all-cause mortality from 1.6 to 5.4%. Further research is required to investigate whether early detection and intervention can slow or stop the progression from asymptomatic to symptomatic HF.
Topics: Aged; Disease Progression; Heart Failure; Humans; Hypertension; Male; Prevalence
PubMed: 35355204
DOI: 10.1007/s11897-022-00542-5